Prohost Letter #418
Observing Queer Stories
PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-ban for extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for a life-threatening VTE . . .
This content is for paid subscribers.
Prohost Letters
March 2, 2018